🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Karen A. Cadoo

Trinity College Dublin

ORCID: 0000-0002-8384-7148

Also affiliated with St. James's Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.352Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer

JCSM Clinical Reports(2020)10.1002/crt2.15
Top 50%
0.352DataRank
Top 50%5 citations

Marcus D. Goncalves, Qin Zhou, Alexia Iasonos, Darragh Halpenny, Andrew J. Plodkowski +7 more

Papers

Driven by 20 papers — median percentile 50. Top paper: “Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer”.

Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-21-1287
N/A
0.524DataRank · unranked
32 citations

Chaitanya Bandlamudi, Matthew D. Hellmann, Yelena Kemel, Esther Drill, Hira Rizvi +32 more

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer

JCSM Clinical Reports(2020)10.1002/crt2.15
Top 50%
0.352DataRank
Top 50%5 citations

Marcus D. Goncalves, Qin Zhou, Alexia Iasonos, Darragh Halpenny, Andrew J. Plodkowski +7 more

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination

npj Breast Cancer(2021)10.1038/s41523-021-00339-0
N/A
0DataRank · unranked
28 citations

Pier Selenica, Semanti Mukherjee, Rachna Shah, Isabella L. Pecorari, Biko McMillan +16 more

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

Gynecologic Oncology Reports(2021)10.1016/j.gore.2021.100873
N/A
0DataRank · unranked
12 citations

Duaa H. Al-Rawi, Ying Liu, Maria M. Rubinstein, Claire F. Friedman, Raajit K. Rampal +4 more

Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.02.006
N/A
0DataRank · unranked
5 citations

Silvana Pedra Nobre, Nisha Pradhan, Maya Yasukawa, Qin Zhou, Alexia Iasonos +11 more

Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5575
N/A
0DataRank · unranked
1 citations

Karen A. Cadoo, Sarah Chiang, Jennifer J. Mueller, Martee L. Hensley, Roisin E. O’Cearbhaill +1 more

Early age of onset and broad cancer spectrum persist in MSH6 and PMS2-associated Lynch syndrome.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10516
N/A
0DataRank · unranked
0 citations

Karen A. Cadoo, Anna Maio, Zalak Patel, Yelena Kemel, Erin Salo‐Mullen +15 more

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1134
N/A
0DataRank · unranked
73 citations

Pier Selenica, Juber Patel, Michelle Wu, Josip Ninčević, Yulia Lakhman +25 more

Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.10.003
N/A
0DataRank · unranked
48 citations

Dib Sassine, Alli Straubhar, Aaron Praiss, Carol Aghajanian, Kaled M. Alektiar +17 more

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.028
N/A
0DataRank · unranked
23 citations

Eric Rios Doria, Jason Konner, Stuart M. Lichtman, Qin Zhou, Alexia Iasonos +18 more

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1006
N/A
0DataRank · unranked
14 citations

Karissa Whiting, Preethi Srinivasan, Chaitanya Bandlamudi, Aliya Khurram, Vijai Joseph +26 more

Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.100980
N/A
0DataRank · unranked
4 citations

Karen A. Cadoo, Sarah Chiang, Diana Mandelker, Raazi Bajwa, Alexia Iasonos +5 more

Comprehensive analysis of germline drivers in endometrial cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad016
N/A
0DataRank · unranked
21 citations

Eric Rios‐Doria, Karen A. Cadoo, Amanda Catchings, Anna Maio, Yelena Kemel +37 more

Pathogenic germline variants in patients with endometrial cancer of diverse ancestry

Cancer(2023)10.1002/cncr.35071
N/A
0DataRank · unranked
14 citations

Sushmita Gordhandas, Kanika Arora, Eric Rios‐Doria, Karen A. Cadoo, Amanda Catchings +26 more

Prevalence of mismatch repair deficiency in a large prospective prostate cancer cohort.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5031
N/A
0DataRank · unranked
1 citations

Mutaz Mohammed Nur, Cathal Ó’Brien, Brianán McGovern, Julia McFadden, Anne‐Marie Baird +11 more

Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

(2023)10.1158/1078-0432.c.6532764
N/A
0DataRank · unranked
0 citations

Karissa Whiting, Preethi Srinivasan, Chaitanya Bandlamudi, Aliya Khurram, Vijai Joseph +26 more

Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

(2023)10.1158/1078-0432.c.6532764.v1
N/A
0DataRank · unranked
0 citations

Karissa Whiting, Preethi Srinivasan, Chaitanya Bandlamudi, Aliya Khurram, Vijai Joseph +26 more

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.10.019
N/A
0DataRank · unranked
16 citations

Rachel N. Grisham, Karen A. Cadoo, Chrisann Kyi, William P. Tew, Claire F. Friedman +14 more

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.11.020
N/A
0DataRank · unranked
0 citations

Bhavana Pothuri, Karen A. Cadoo, Yvette Drew, Rachel Miller-Garcia, Deborah K. Armstrong +2 more

Prevalence and clinical characterization of MMR-D/MSI extra-colonic cancers among germline PMS2 mutation carriers.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1527
N/A
0DataRank · unranked
1 citations

Erin Salo‐Mullen, Amanda Catchings, Megha Ranganathan, Elise Fiala, Yelena Kemel +15 more